接受利福平治疗的婴儿每日两次多替拉韦给药:EMPIRICAL 试验的药代学子研究
该药代学子研究纳入30名1-12月龄HIV感染婴儿,比较接受利福平抗结核治疗时多替拉韦每日两次给药与未接受利福平时每日一次给药的药代动力学。结果显示每日两次给药组多替拉韦暴露量与每日一次组相当,支持HIV-TB合并感染婴儿采用此方案。
要点
- 接受利福平的婴儿每日两次多替拉韦给药,AUC0-24h几何均值比为0.91(95%CI 0.59-1.42)。
- 利福平组1例(5%)多替拉韦Ctrough<0.32 mg/L,无Ctrough<0.064 mg/L者。
- 利福平组多替拉韦代谢比值为无利福平组的2.3倍。
核心结论
- 接受利福平的婴儿每日两次多替拉韦给药可获得足够的多替拉韦暴露,支持该方案用于HIV-TB合并感染婴儿。
研究设计与样本
- EMPIRICAL试验的药代学子研究,纳入30名1-12月龄、体重≥3 kg的HIV感染婴儿,其中27名有可评估药代动力学曲线。
- 接受利福平抗结核治疗者多替拉韦每日两次给药,未接受利福平者每日一次给药;每日两次组采血6次覆盖12小时,每日一次组覆盖24小时。
主要发现
- 纳入婴儿中位年龄7.1月(四分位距6.1-9.9),中位体重6.3 kg(5.6-7.2),21名(78%)接受利福平,11名(41%)为女性。
- 每日两次多替拉韦加利福平组与每日一次多替拉韦无利福平组相比,AUC0-24h几何均值比0.91(95%CI 0.59-1.42),Ctrough几何均值比0.95(95%CI 0.57-1.59),Cmax几何均值比0.87(95%CI 0.57-1.33)。
- 利福平组1名婴儿(5%)多替拉韦Ctrough<0.32 mg/L,无利福平组无此类婴儿;两组均无Ctrough<0.064 mg/L者。
- 利福平组多替拉韦代谢比值(多替拉韦-葡萄糖醛酸苷AUC/多替拉韦AUC)为无利福平组的2.3倍。
- 82例报告的不良事件中5例可能与利福平或多替拉韦相关,均未经停药而缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated dolutegravir pharmacokinetics in infants with human immunodeficiency virus (HIV) receiving dolutegravir twice daily (BID) with rifampicin-based tuberculosis (TB) treatment compared with once daily (OD) without rifampicin. METHODS: Infants with HIV aged 1-12 months, weighing ≥3 kg, and receiving dolutegravir BID with rifampicin or OD without rifampicin were eligible. Six blood samples were taken over 12 (BID) or 24 hours (OD). Dolutegravir pharmacokinetic parameters, HIV viral load (VL) data, and adverse events (AEs) were reported. RESULTS: Twenty-seven of 30 enrolled infants had evaluable pharmacokinetic curves. The median (interquartile range) age was 7.1 months (6.1-9.9), weight was 6.3 kg (5.6-7.2), 21 (78%) received rifampicin, and 11 (41%) were female. Geometric mean ratios comparing dolutegravir BID with rifampicin versus OD without rifampicin were area under curve (AUC)0-24h 0.91 (95% confidence interval, .59-1.42), Ctrough 0.95 (0.57-1.59), Cmax 0.87 (0.57-1.33). One infant (5%) receiving rifampicin versus none without rifampicin had dolutegravir Ctrough <0.32 mg/L, and none had Ctrough <0.064 mg/L. The dolutegravir metabolic ratio (dolutegravir-glucuronide AUC/dolutegravir AUC) was 2.3-fold higher in combination with rifampicin versus without rifampicin. Five of 82 reported AEs were possibly related to rifampicin or dolutegravir and resolved without treatment discontinuation. Upon TB treatment completion, HIV viral load was <1000 copies/mL in 76% and 100% of infants and undetectable in 35% and 20% of infants with and without rifampicin, respectively. CONCLUSIONS: Dolutegravir BID in infants receiving rifampicin resulted in adequate dolutegravir exposure, supporting this treatment approach for infants with HIV-TB coinfection.
引用
- Jacobs TG, Mumbiro V, Cassia U, et al. Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial. Clin Infect Dis. 2024. PMID: 37882611. doi:10.1093/cid/ciad656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。